Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This review article summarizes the potential role of advanced medical therapies—using genes, cells, and/or tissue engineering—in treating various types of alopecia, by examining clinical research, basic studies, and ongoing trials.

Hair transplantation can successfully treat stubborn alopecia areata.

In this study, researchers found that alopecia areata is linked to immune cell activation against hair follicle autoantigens and is associated with heart changes and cardiac marker alterations in humans and mice.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This review discusses alopecia areata as a model for studying tissue-directed autoimmune diseases and reports no new clinical findings.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This study observed that alopecia areata can be induced and serially transferred in C3H/HeJ mice using skin grafts, providing a useful model for studying the disease in humans.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

In this study, co-grafting human keratinocytes with murine dermal papilla-enriched cells produced hair follicle-like structures, but without regular hair formation, suggesting anomalous folliculogenesis.

This review discusses androgenetic alopecia and alopecia areata through a systems biology lens, emphasizing the role of multi-omics data integration to explore molecular mechanisms and potential therapeutic strategies, but offers no new clinical results.

In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This article discusses the etiology, clinical features, diagnosis, histopathology, and treatment of alopecia areata but reports no new clinical findings; it emphasizes the palliative nature of current treatments.

This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.

This study found that gonadal steroid hormones influence alopecia areata in C3H/HeJ mice, with estradiol promoting progression and dihydrotestosterone conferring resistance to disease onset.

In this study, anthralin treatment led to hair regrowth in alopecia areata-like affected C3H/HeJ mice, suggesting it may be an effective therapy for this condition.

In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.

This review discusses recent advances in understanding the pathogenesis of autoimmune alopecia areata and reports no new clinical results; it highlights potential for developing more effective treatments.

This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.

This study found that 363 genes were differentially expressed in alopecia areata skin compared to non-lesional skin, suggesting T-cell mediated immune responses and distinct gene profiles related to the disease's stage.

This review discusses rodent models of alopecia areata and suggests they are crucial for understanding the autoimmune mechanisms and potential treatments but reports no new clinical results.

This study found that mechlorethamine restored hair growth in mice with alopecia-areata-like disease by eliminating infiltrated lymphocytes and inhibiting certain pro-inflammatory cytokines in treated skin areas.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

This article reviews the genetic and potential environmental factors in alopecia areata's pathogenesis and suggests a polygenic model but reports no new clinical findings.

This study found that MDA-modified DNA may contribute to immune responses in alopecia areata patients by creating neo-epitopes, providing new insights into the condition's immunological mechanisms.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.